Search

Your search keyword '"Ghesquières, H."' showing total 218 results
Start Over Author "Ghesquières, H."
218 results on '"Ghesquières, H."'

3. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)

Author

Ghesquieres, H., Chevrier, M., Laadhari, M., Chinot, O., Choquet, S., Moluçon-Chabrot, C., Beauchesne, P., Gressin, R., Morschhauser, F., Schmitt, A., Gyan, E., Hoang-Xuan, K., Nicolas-Virelizier, E., Cassoux, N., Touitou, V., Le Garff-Tavernier, M., Savignoni, A., Turbiez, I., Soumelis, V., Houillier, C., and Soussain, C.

Published
2019
Full Text
View/download PDF

4. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers

Author

Fossard, G., Broussais, F., Coelho, I., Bailly, S., Nicolas-Virelizier, E., Toussaint, E., Lancesseur, C., Le Bras, F., Willems, E., Tchernonog, E., Chalopin, T., Delarue, R., Gressin, R., Chauchet, A., Gyan, E., Cartron, G., Bonnet, C., Haioun, C., Damaj, G., Gaulard, P., Fornecker, L., Ghesquières, H., Tournilhac, O., da Silva, M. Gomes, Bouabdallah, R., Salles, G., and Bachy, E.

Published
2018
Full Text
View/download PDF

6. Efficacy of anti‐PD1 therapy in relapsed or refractory NK/T cell lymphoma: a matched cohort analysis from the LYSA

Author

Marouf, A., primary, Chaubard, S., additional, Michot, J., additional, Liévin, R., additional, Rossignol, J., additional, Golfier, C., additional, Allangba, O., additional, Philippe, L., additional, Tessoulin, B., additional, Chauchet, A., additional, Deau, B., additional, Oberic, L., additional, Vargaftig, J., additional, Moignet, A., additional, Clavert, A., additional, Dulery, R., additional, Brisou, G., additional, Tardy, S., additional, Fataccioli, V., additional, Houot, R., additional, Casasnovas, R., additional, Thieblemont, C., additional, Ghesquières, H., additional, Carras, S., additional, Le Gouill, S., additional, Cartron, G., additional, Marabelle, A., additional, Tournilhac, O., additional, Damaj, G., additional, Gaulard, P., additional, De Leval, L., additional, Lemonnier, F., additional, Bachy, E., additional, Hermine, O., additional, Couronné, L., additional, and Jaccard, A., additional

Published
2023
Full Text
View/download PDF

10. Corrigendum to ‘Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers’

Author

Fossard, G., primary, Broussais, F., additional, Coelho, I., additional, Bailly, S., additional, Nicolas-Virelizier, E., additional, Toussaint, E., additional, Lancesseur, C., additional, Le Bras, F., additional, Willems, E., additional, Tchernonog, E., additional, Chalopin, T., additional, Delarue, R., additional, Gressin, R., additional, Chauchet, A., additional, Gyan, E., additional, Cartron, G., additional, Bonnet, C., additional, Haioun, C., additional, Damaj, G., additional, Gaulard, P., additional, Fornecker, L., additional, Ghesquières, H., additional, Tournilhac, O., additional, Gomesda Silva, M., additional, Bouabdallah, R., additional, Salles, G., additional, and Bachy, E., additional

Published
2021
Full Text
View/download PDF

12. Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study

Author

Leclerc, V., primary, Karlin, L., additional, Herledan, C., additional, Marchal, L., additional, Baudouin, A., additional, Gouraud, A., additional, Caffin, A. G., additional, Larbre, V., additional, Lazareth, A., additional, Bachy, E., additional, Salles, G., additional, Ghesquières, H., additional, Rioufol, C., additional, and Ranchon, F., additional

Published
2021
Full Text
View/download PDF

13. LONG‐TERM OUTCOMES OF ELDERLY PATIENTS TREATED WITH FRONTLINE R‐CHOP: UPDATE OF THE LNH03‐6B TRIAL

Author

Camus, V., primary, Belot, Aurél., additional, Oberic, L., additional, Sibon, D., additional, Ghesquières, H., additional, Thieblemont, C., additional, Fruchart, C., additional, Casasnovas, O., additional, Michot, Jean‐M., additional, Molina, T. J., additional, Bosly, A., additional, Joubert, Clém., additional, Haioun, C., additional, Delarue, R., additional, and Tilly, H., additional

Published
2021
Full Text
View/download PDF

14. Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways

Author

Kleinstern, G., Yan, H., Hildebrandt, M.A.T., Vijai, J., Berndt, S.I., Ghesquières, H., McKay, J., Nieters, A., Ye, Y., Monnereau, A., Brooks-Wilson, A.R., Lan, Q., Melbye, M., Jackson, R.D., Teras, L.R., Purdue, M.P., Vajdic, C.M., Vermeulen, R.C.H., Giles, G.G., Cocco, P.L., Birmann, B.M., Kraft, P., Albanes, D., Zeleniuch-Jacquotte, A., Crouch, S., Sarangi, V., Asmann, Y., Offit, K., Salles, G., Smedby, K.E., Skibola, C.F., Slager, S.L., Rothman, N., Chanock, S.J., Cerhan, J.R., IRAS OH Epidemiology Chemical Agents, and dIRAS RA-2

Abstract

We previously identified five single nucleotide polymorphisms (SNPs) at four susceptibility loci for diffuse large B-cell lymphoma (DLBCL) in individuals of European ancestry through a large genome-wide association study (GWAS). To further elucidate genetic susceptibility to DLBCL, we sought to validate two loci at 3q13.33 and 3p24.1 that were suggestive in the original GWAS with additional genotyping. In the meta-analysis (5662 cases and 9237 controls) of the four original GWAS discovery scans and three replication studies, the 3q13.33 locus (rs9831894; minor allele frequency [MAF] = 0.40) was associated with DLBCL risk [odds ratio (OR) = 0.83, P = 3.62 × 10−13]. rs9831894 is in linkage disequilibrium (LD) with additional variants that are part of a super-enhancer that physically interacts with promoters of CD86 and ILDR1. In the meta-analysis (5510 cases and 12 817 controls) of the four GWAS discovery scans and four replication studies, the 3p24.1 locus (rs6773363; MAF = 0.45) was also associated with DLBCL risk (OR = 1.20, P = 2.31 × 10−12). This SNP is 29 426-bp upstream of the nearest gene EOMES and in LD with additional SNPs that are part of a highly lineage-specific and tumor-acquired super-enhancer that shows long-range interaction with AZI2 promoter. These loci provide additional evidence for the role of immune function in the etiology of DLBCL, the most common lymphoma subtype.

Published
2020

15. Genetically Determined Height and Risk of Non-hodgkin Lymphoma

Author

Moore, A., Kane, E., Panagiotou, O.A., Teras, L.R., Monnereau, A., Wong Doo, N., Machiela, M.J., Skibola, C.F., Slager, S.L., Salles, G., Camp, N.J., Bracci, P.M., Nieters, A., Vermeulen, R.C.H., Vijai, J., Smedby, K.E., Vajdic, C.M., Cozen, W., Spinelli, J.J., Hjalgrim, H., Giles, G.G., Link, B.K., Clavel, J., Arslan, A.A., Purdue, M.P., Tinker, L.F., Albanes, D., Ferri, G.M., Habermann, T.M., Adami, H.-O., Becker, N., Benavente, Y., Bisanzi, S., Boffetta, P., Brennan, P., Brooks-Wilson, A.R., Canzian, F., Conde, L., Cox, D.G., Curtin, K., Foretova, L., Gapstur, S.M., Ghesquières, H., Glenn, M., Glimelius, B., Jackson, R.D., Lan, Q., Liebow, M., Maynadie, M., McKay, J., Melbye, M., Miligi, L., Milne, R.L., Molina, T.J., Morton, L.M., North, K.E., Offit, K., Padoan, M., Piro, S., Ravichandran, V., Riboli, E., de Sanjose, S., Severson, R.K., Southey, M.C., Staines, A., Stewart, C., Travis, R.C., Weiderpass, E., Weinstein, S., Zheng, T., Chanock, S.J., Chatterjee, N., Rothman, N., Birmann, B.M., Cerhan, J.R., Berndt, S.I., IRAS OH Epidemiology Chemical Agents, and dIRAS RA-2

Subjects
follicular lymphoma, non-Hodgkin lymphoma, polygenic risk score, diffuse large B-celllymphoma, chronic lymphocytic leukemia, genetics, marginal zone lymphoma, height
Abstract

Although the evidence is not consistent, epidemiologic studies have suggested that taller adult height may be associated with an increased risk of some non-Hodgkin lymphoma (NHL) subtypes. Height is largely determined by genetic factors, but how these genetic factors may contribute to NHL risk is unknown. We investigated the relationship between genetic determinants of height and NHL risk using data from eight genome-wide association studies (GWAS) comprising 10,629 NHL cases, including 3,857 diffuse large B-cell lymphoma (DLBCL), 2,847 follicular lymphoma (FL), 3,100 chronic lymphocytic leukemia (CLL), and 825 marginal zone lymphoma (MZL) cases, and 9,505 controls of European ancestry. We evaluated genetically predicted height by constructing polygenic risk scores using 833 height-associated SNPs. We used logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) for association between genetically determined height and the risk of four NHL subtypes in each GWAS and then used fixed-effect meta-analysis to combine subtype results across studies. We found suggestive evidence between taller genetically determined height and increased CLL risk (OR = 1.08, 95% CI = 1.00–1.17, p = 0.049), which was slightly stronger among women (OR = 1.15, 95% CI: 1.01–1.31, p = 0.036). No significant associations were observed with DLBCL, FL, or MZL. Our findings suggest that there may be some shared genetic factors between CLL and height, but other endogenous or environmental factors may underlie reported epidemiologic height associations with other subtypes.

Published
2020

16. Genetically Determined Height and Risk of Non-hodgkin Lymphoma

Author

IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Moore, A., Kane, E., Panagiotou, O.A., Teras, L.R., Monnereau, A., Wong Doo, N., Machiela, M.J., Skibola, C.F., Slager, S.L., Salles, G., Camp, N.J., Bracci, P.M., Nieters, A., Vermeulen, R.C.H., Vijai, J., Smedby, K.E., Vajdic, C.M., Cozen, W., Spinelli, J.J., Hjalgrim, H., Giles, G.G., Link, B.K., Clavel, J., Arslan, A.A., Purdue, M.P., Tinker, L.F., Albanes, D., Ferri, G.M., Habermann, T.M., Adami, H.-O., Becker, N., Benavente, Y., Bisanzi, S., Boffetta, P., Brennan, P., Brooks-Wilson, A.R., Canzian, F., Conde, L., Cox, D.G., Curtin, K., Foretova, L., Gapstur, S.M., Ghesquières, H., Glenn, M., Glimelius, B., Jackson, R.D., Lan, Q., Liebow, M., Maynadie, M., McKay, J., Melbye, M., Miligi, L., Milne, R.L., Molina, T.J., Morton, L.M., North, K.E., Offit, K., Padoan, M., Piro, S., Ravichandran, V., Riboli, E., de Sanjose, S., Severson, R.K., Southey, M.C., Staines, A., Stewart, C., Travis, R.C., Weiderpass, E., Weinstein, S., Zheng, T., Chanock, S.J., Chatterjee, N., Rothman, N., Birmann, B.M., Cerhan, J.R., Berndt, S.I., IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Moore, A., Kane, E., Panagiotou, O.A., Teras, L.R., Monnereau, A., Wong Doo, N., Machiela, M.J., Skibola, C.F., Slager, S.L., Salles, G., Camp, N.J., Bracci, P.M., Nieters, A., Vermeulen, R.C.H., Vijai, J., Smedby, K.E., Vajdic, C.M., Cozen, W., Spinelli, J.J., Hjalgrim, H., Giles, G.G., Link, B.K., Clavel, J., Arslan, A.A., Purdue, M.P., Tinker, L.F., Albanes, D., Ferri, G.M., Habermann, T.M., Adami, H.-O., Becker, N., Benavente, Y., Bisanzi, S., Boffetta, P., Brennan, P., Brooks-Wilson, A.R., Canzian, F., Conde, L., Cox, D.G., Curtin, K., Foretova, L., Gapstur, S.M., Ghesquières, H., Glenn, M., Glimelius, B., Jackson, R.D., Lan, Q., Liebow, M., Maynadie, M., McKay, J., Melbye, M., Miligi, L., Milne, R.L., Molina, T.J., Morton, L.M., North, K.E., Offit, K., Padoan, M., Piro, S., Ravichandran, V., Riboli, E., de Sanjose, S., Severson, R.K., Southey, M.C., Staines, A., Stewart, C., Travis, R.C., Weiderpass, E., Weinstein, S., Zheng, T., Chanock, S.J., Chatterjee, N., Rothman, N., Birmann, B.M., Cerhan, J.R., and Berndt, S.I.

Published
2020

17. Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways

Author

IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Kleinstern, G., Yan, H., Hildebrandt, M.A.T., Vijai, J., Berndt, S.I., Ghesquières, H., McKay, J., Nieters, A., Ye, Y., Monnereau, A., Brooks-Wilson, A.R., Lan, Q., Melbye, M., Jackson, R.D., Teras, L.R., Purdue, M.P., Vajdic, C.M., Vermeulen, R.C.H., Giles, G.G., Cocco, P.L., Birmann, B.M., Kraft, P., Albanes, D., Zeleniuch-Jacquotte, A., Crouch, S., Sarangi, V., Asmann, Y., Offit, K., Salles, G., Smedby, K.E., Skibola, C.F., Slager, S.L., Rothman, N., Chanock, S.J., Cerhan, J.R., IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Kleinstern, G., Yan, H., Hildebrandt, M.A.T., Vijai, J., Berndt, S.I., Ghesquières, H., McKay, J., Nieters, A., Ye, Y., Monnereau, A., Brooks-Wilson, A.R., Lan, Q., Melbye, M., Jackson, R.D., Teras, L.R., Purdue, M.P., Vajdic, C.M., Vermeulen, R.C.H., Giles, G.G., Cocco, P.L., Birmann, B.M., Kraft, P., Albanes, D., Zeleniuch-Jacquotte, A., Crouch, S., Sarangi, V., Asmann, Y., Offit, K., Salles, G., Smedby, K.E., Skibola, C.F., Slager, S.L., Rothman, N., Chanock, S.J., and Cerhan, J.R.

Published
2020

20. Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes

Author

Din, L., Sheikh, M., Kosaraju, N., Smedby, K.E., Bernatsky, S., Berndt, S.I., Skibola, C.F., Nieters, A., McKay, J.D., Cocco, P., Maynadié, M., Foretová, L., Staines, A., Mack, T.M., de Sanjosé, S., Vyse, T.J., Padyukov, L., Monnereau, A., Arslan, A.A., Moore, A., Brooks-Wilson, A.R., Glimelius, B., Birmann, B.M., Link, B.K., Stewart, C., Vajdic, C.M., Haioun, C., Magnani, C., Conti, D.V., Cox, D.G., Casabonne, D., Albanes, D., Kane, E., Roman, E., Muzi, G., Salles, G., Giles, G.G., Adami, H.-O., Ghesquières, H., De Vivo, I., Clavel, J., Cerhan, J.R., Spinelli, J.J., Vijai, J., Curtin, K., Costenbader, K.H., Onel, K., Offit, K., Teras, L.R., Morton, L., Conde, L., Miligi, L., Melbye, M., Ennas, M.G., Liebow, M., Purdue, M.P., Glenn, M., Southey, M.C., Din, M., Rothman, N., Camp, N.J., Wong Doo, N., Becker, N., Pradhan, N., Bracci, P.M., Boffetta, P., Vineis, P., Brennan, P., Kraft, P., Lan, Q., Severson, R.K., Vermeulen, R.C.H., Milne, R.L., Kaaks, R., Travis, R.C., Weinstein, S.J., Chanock, S.J., Ansell, S.M., Slager, S.L., Zheng, T., Benavente, Y., Taub, Z., Madireddy, L., Gourraud, P.-A., Oksenberg, J.R., Cozen, W., Hjalgrim, H., Khankhanian, P., Din, L., Sheikh, M., Kosaraju, N., Smedby, K.E., Bernatsky, S., Berndt, S.I., Skibola, C.F., Nieters, A., McKay, J.D., Cocco, P., Maynadié, M., Foretová, L., Staines, A., Mack, T.M., de Sanjosé, S., Vyse, T.J., Padyukov, L., Monnereau, A., Arslan, A.A., Moore, A., Brooks-Wilson, A.R., Glimelius, B., Birmann, B.M., Link, B.K., Stewart, C., Vajdic, C.M., Haioun, C., Magnani, C., Conti, D.V., Cox, D.G., Casabonne, D., Albanes, D., Kane, E., Roman, E., Muzi, G., Salles, G., Giles, G.G., Adami, H.-O., Ghesquières, H., De Vivo, I., Clavel, J., Cerhan, J.R., Spinelli, J.J., Vijai, J., Curtin, K., Costenbader, K.H., Onel, K., Offit, K., Teras, L.R., Morton, L., Conde, L., Miligi, L., Melbye, M., Ennas, M.G., Liebow, M., Purdue, M.P., Glenn, M., Southey, M.C., Din, M., Rothman, N., Camp, N.J., Wong Doo, N., Becker, N., Pradhan, N., Bracci, P.M., Boffetta, P., Vineis, P., Brennan, P., Kraft, P., Lan, Q., Severson, R.K., Vermeulen, R.C.H., Milne, R.L., Kaaks, R., Travis, R.C., Weinstein, S.J., Chanock, S.J., Ansell, S.M., Slager, S.L., Zheng, T., Benavente, Y., Taub, Z., Madireddy, L., Gourraud, P.-A., Oksenberg, J.R., Cozen, W., Hjalgrim, H., and Khankhanian, P.

Abstract

Epidemiologic studies show an increased risk of non-Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen-stimulation in one disease leads to another. Here we assess shared genetic risk in genome-wide-association-studies (GWAS). Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (a) description of regional genetic of overlap, (b) polygenic risk score (PRS), (c)"diseasome", (d)meta-analysis. Descriptive analysis revealed few shared genetic factors between each AD and each NHL subtype. The PRS of ADs were not increased in NHL patients (nor vice versa). In the diseasome, NHLs shared more genetic etiology with ADs than solid cancers (p = .0041). A meta-analysis (combing AD with NHL) implicated genes of apoptosis and telomere length. This GWAS-based analysis four NHL subtypes and three ADs revealed few weakly-associated shared loci, explaining little total risk. This suggests common genetic variation, as assessed by GWAS in these sample sizes, may not be the primary explanation for the link between these ADs and NHLs.

Published
2019

23. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

Author

Soussain, C., primary, Choquet, S., additional, Blonski, M., additional, Leclercq, D., additional, Houillier, C., additional, Rezai, K., additional, Bijou, F., additional, Houot, R., additional, Boyle, E., additional, Gressin, R., additional, Nicolas-Virelizier, E., additional, Barrie, M., additional, Moluçon-Chabrot, C., additional, Lelez, M.L., additional, Clavert, A., additional, Coisy, S., additional, Leruez, S., additional, Touitou, V., additional, Cassoux, N., additional, Daniau, M., additional, Ertault de la Bretonnière, M., additional, El Yamani, A., additional, Ghesquières, H., additional, and Hoang-Xuan, K., additional

Published
2019
Full Text
View/download PDF

24. ONE-YEAR REAL-LIFE TARGETED NEXT GENERATION SEQUENCING FOR LYMPHOMA DIAGNOSIS: STUDY OF PATIENTS FROM THE FRENCH LYMPHOMA NETWORK IN RHÔNE-ALPES

Author

Bommier, C., primary, Mauduit, C., additional, Fontaine, J., additional, Bourbon, E., additional, Sujobert, P., additional, Huet, S., additional, Baseggio, L., additional, Hayette, S., additional, Laurent, C., additional, Bachy, E., additional, Ghesquières, H., additional, Salles, G., additional, and Traverse-Glehen, A., additional

Published
2019
Full Text
View/download PDF

25. BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: a RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY

Author

Bazarbachi, A., primary, Boumendil, A., additional, Finel, H., additional, Mohty, M., additional, Castagna, L., additional, Blaise, D., additional, Peggs, K., additional, Afanasyev, B., additional, Diez-Martin, J., additional, Corradini, P., additional, Socié, G., additional, Robinson, S., additional, Gutiérrez-García, G., additional, Bonifazi, F., additional, Yakoub-Agha, I., additional, Gülbas, Z., additional, Bloor, A., additional, Delage, J., additional, Esquirol, A., additional, Malladi, R., additional, Scheid, C., additional, Ghesquières, H., additional, Montoto, S., additional, Dreger, P., additional, and Sureda, A., additional

Published
2017
Full Text
View/download PDF

27. IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO-RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END-POINT OF THE I LOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK.

Author

Soussain, C., primary, Choquet, S., additional, Houillier, C., additional, Bijou, F., additional, Houot, R., additional, Boyle, E., additional, Gressin, R., additional, Nicolas-Virelizier, E., additional, Barrie, M., additional, Moluçon-Chabrot, C., additional, Lelez, M., additional, Clavert, A., additional, Coisy, S., additional, de la Bretonnière, M. Ertault, additional, El Yamani, A., additional, Touitou, V., additional, Cassoux, N., additional, Boussetta, S., additional, Broussais, F., additional, Gelas-Dore, B., additional, Barzic, N., additional, Ghesquières, H., additional, and Hoang-Xuan, K., additional

Published
2017
Full Text
View/download PDF

28. Distinct molecular determinants of treatment‐failure in elderly Hodgkin lymphoma identified by cell‐free DNA profiling: A LYSA Study.

Author

Rossi, C., Boegeholz, J. L., Alig, S. K., Garofolo, A., Esfahani, M. Shahrokh, Schroers‐Martin, J., Olsen, M., Kang, X., Kurtz, D. M., Sugio, T., Hamilton, M. P., André, M., Casasnovas, O., Diehn, M., Ghesquières, H., and Alizadeh, A. A.

Subjects
CELL-free DNA, DNA fingerprinting, HODGKIN'S disease, OLDER people, CIRCULATING tumor DNA
Abstract

Distinct molecular determinants of treatment-failure in elderly Hodgkin lymphoma identified by cell-free DNA profiling: A LYSA Study Interestingly, pre-treatment ctDNA levels did not differ between EBV+ and EBV- tumors ( I p i = 0.92), while specific genetic aberrations were significantly associated with respective EBV status (Figure C). Older HL pts, especially those with high baseline ctDNA levels and/or EBV+ tumors, have an exceedingly high risk of treatment failure with conventional chemotherapy, and likely require future risk-adapted strategies. [Extracted from the article]

Published
2023
Full Text
View/download PDF

30. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial

Author

Tabouret, E., primary, Houillier, C., additional, Martin-Duverneuil, N., additional, Blonski, M., additional, Soussain, C, additional, Ghesquières, H., additional, Houot, R., additional, Larrieu, D., additional, Soubeyran, P., additional, Gressin, R., additional, Gyan, E., additional, Chinot, O., additional, Taillandier, L., additional, Choquet, S., additional, Alentorn, A., additional, Leclercq, D., additional, Omuro, A., additional, Tanguy, M.L., additional, and Hoang-Xuan, K., additional

Published
2016
Full Text
View/download PDF

36. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): A randomised phase 3 trial

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, Delarue, R., Tilly, H., Mounier, N., Petrella, T., Salles, G., Thieblemont, C., Bologna, S., Ghesquières, H., Hacini, M., Fruchart, C., Ysebaert, L., Fermé, C., Casasnovas, O., Van Hoof, A., Thyss, A., Delmer, A., Fitoussi, O., Molina, T.J., Haioun, C., Bosly, André, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, Delarue, R., Tilly, H., Mounier, N., Petrella, T., Salles, G., Thieblemont, C., Bologna, S., Ghesquières, H., Hacini, M., Fruchart, C., Ysebaert, L., Fermé, C., Casasnovas, O., Van Hoof, A., Thyss, A., Delmer, A., Fitoussi, O., Molina, T.J., Haioun, C., and Bosly, André

Abstract

Background: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become the standard of care for elderly patients with diffuse large B-cell lymphoma. We aimed to ascertain if a dose-dense R-CHOP regimen administered every 2 weeks (R-CHOP14) was superior to the standard 3-week schedule (R-CHOP21). Methods: We did a randomised phase 3 trial at 83 centres in four countries. 602 patients aged 60-80 years with untreated diffuse large B-cell lymphoma and at least one adverse prognostic factor (age-adjusted international prognostic index ≥1) were eligible for the study. We randomly allocated individuals to R-CHOP-ie, rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), vincristine (1·4 mg/m2, up to 2 mg) all on day 1, and prednisone 40 mg/m2 daily for 5 days-administered every 14 days (n=304) or every 21 days (n=298) for eight cycles. We did permuted-block randomisation (block size four, allocation ratio 1:1) stratified by centre and number of adverse prognostic factors. The primary endpoint was event-free survival. Our analysis was of the intention-to-treat population, and we present the final analysis. This study is registered with ClinicalTrials.gov, number NCT00144755. Findings: Two patients allocated R-CHOP21 were ineligible for the study and were excluded from analyses. After median follow-up of 56 months (IQR 27-60), 3-year event-free survival was 56% (95% CI 50-62) in the R-CHOP14 group and 60% (55-66) in the R-CHOP21 group (hazard ratio 1·04, 95% CI 0·82-1·31; p=0·7614). Grade 3-4 neutropenia occurred in 224 (74%) of 304 patients allocated R-CHOP14 and 189 (64%) of 296 assigned R-CHOP21, despite increased use of granulocyte colony-stimulating factor in the R-CHOP14 group compared with the R-CHOP21 group. 143 (47%) patients in the R-CHOP14 group received at least one red-blood-cell transfusion versus 93 (31%) in the R-CHOP21 group (p=0·0001). 35 (12%) patients allocated R-CHOP14 receiv

Published
2013

37. PCN60 COST-EFFECTIVENESS OF PEGFILGRASTIM VERSUS FILGRASTIM AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMA AND MYELOMA

Author

Perrier, L., primary, Lefranc, A., additional, Quittet, P., additional, Moreau, P., additional, Siani, C., additional, Ghesquières, H., additional, Jardin, F., additional, Favier, B., additional, Ifrah, N., additional, Lissandre, S., additional, Pérol, D., additional, and Sebban, C., additional

Published
2011
Full Text
View/download PDF

43. Combination of rituximab with chemotherapy in diffuse large ß-cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication.

Author

Ghesquières H, Ferlay C, Sebban C, Chassagne C, Carausu L, Gargi T, Favier B, Philip I, Blay J, and Biron P

Abstract

Randomized trials have demonstrated improved outcome from adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) for patients with diffuse large B-cell lymphoma (DLBCL). This retrospective study compared the outcomes of 224 patients with DLBCL treated in our institution before (Period 1, 1996-2002) and after (Period 2, 2002-2005) approval of rituximab in this indication to evaluate the impact of the drug in daily practice in unselected patients receiving different types of chemotherapy. We treated 131 patients in Period 1 versus 93 in Period 2 (median follow-up, 75 and 29 months, respectively) with no difference in patient characteristics between the two periods. Event-free and overall survivals (EFS and OS) were significantly improved in Period 2 for elderly patients and a significant shift in the selection of regimens was observed at the time when rituximab became available. More patients received the CHOP regimen in Period 2 than in Period 1 (82 vs. 57%, p < 0.007) with CHOP being substituted for epirubicin-based regimens. In younger patients treated mostly with the ACVBP regimen (doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone) these differences were not observed, suggesting that combination of rituximab with dose-dense chemotherapy may deserve further evaluation in this age group. Copyright (c) 2008 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

50. Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma

Author

Mariagrazia Zucca, Thomas M. Habermann, Lauren R. Teras, Joseph Vijai, Lenka Foretova, Simon Crouch, Anneclaire J. De Roos, Jacqueline Clavel, Lindsay M. Morton, Melissa C. Southey, W. Ryan Diver, Patrick M. Gaffney, James McKay, Eve Roman, Sophia S. Wang, Mark P. Purdue, Hans-Olov Adami, Gilles Salles, Jarmo Virtamo, Yan W. Asmann, Angela Brooks-Wilson, Thierry Jo Molina, Andrew D. Zelenetz, Ahmet Dogan, Kenneth Offit, Peter Kraft, Gianluca Severi, Zhaoming Wang, Tongzhang Zheng, Sonja I. Berndt, Brian K. Link, Sasha Bernatsky, Theodore R. Holford, Emanuele Angelucci, Paige M. Bracci, Martyn T. Smith, Stephen J. Chanock, Brenda M. Birmann, Hervé Ghesquières, Stephen M. Ansell, Paolo Vineis, Mads Melbye, Kari E. North, Jenny Turner, Jacques Riby, Charles E. Lawrence, Alain Monnereau, Nikolaus Becker, Lucia Conde, James R. Cerhan, Susan L. Slager, Demetrius Albanes, Henrik Hjalgrim, Hervé Tilly, Héctor A. Velásquez García, Rebecca D. Jackson, Ann E. Clarke, Elizabeth A. Holly, Robert J. Klein, Paolo Boffetta, Mark Liebow, Karin E. Smedby, Marco Rais, David G. Cox, Patricia Hartge, Rosalind Ramsey-Goldman, Rachel S. Kelly, Lesley F. Tinker, Christine F. Skibola, Wendy Cozen, Tracy Lightfoot, Anne J. Novak, Heiner Boeing, Roel Vermeulen, Claire M. Vajdic, Bengt Glimelius, Kimberly A. Bertrand, Marc Maynadie, Eleanor Kane, Nathaniel Rothman, Yolanda Benavente, Paul Brennan, Anne Tjønneland, John J. Spinelli, Qing Lan, Anne Kricker, Alex Smith, Anthony Staines, Graham G. Giles, Carrie A. Thompson, Thomas E. Witzig, Stephanie J. Weinstein, Karen H. Cotenbader, Corinne Haioun, Anne Zeleniuch-Jacquotte, Simonetta Di Lollo, Alexandra Nieters, Rudolph Kaaks, Silvia de Sanjosé, Richard K. Severson, Yawei Zhang, Research Institute of the McGill University Health Centre, 1650 Cedar Avenue, Oklahoma Medical Research Foundation, Registre des hémopathies malignes de Côte d'Or, Centre d'épidémiologie des populations ( CEP ), Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Université Bourgogne Franche-Comté ( UBFC ), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), University of Calgary, Bernatsky, S. and García, H.A.V. and Spinelli, J.J. and Gaffney, P. and Smedby, K.E. and Ramsey-Goldman, R. and Wang, S.S. and Adami, H.-O. and Albanes, D. and Angelucci, E. and Ansell, S.M. and WAsmann, Y. and Becker, N. and Benavente, Y. and Berndt, S.I. and Bertrand, K.A. and Birmann, B.M. and Boeing, H. and Boffetta, P. and Bracci, P.M. and Brennan, P. and Brooks-Wilson, A.R. and Cerhan, J.R. and Chanock, S.J. and Clavel, J. and Conde, L. and Cotenbader, K.H. and Cox, D.G. and Cozen, W. and Crouch, S. and De Roos, A.J. and De Sanjose, S. and Di Lollo, S. and Diver, W.R. and Dogan, A. and Foretova, L. and Ghesquières, H. and Giles, G.G. and Glimelius, B. and Habermann, T.M. and Haioun, C. and Hartge, P. and Hjalgrim, H. and Holford, T.R. and Holly, E.A. and Jackson, R.D. and Kaaks, R. and Kane, E. and Kelly, R.S. and Klein, R.J. and Kraft, P. and Kricker, A. and Lan, Q. and Lawrence, C. and Liebow, M. and Lightfoot, T. and Link, B.K. and Maynadie, M. and McKay, J. and Melbye, M. and Molina, T.J. and Monnereau, A. and Morton, L.M. and Nieters, A. and North, K.E. and Novak, A.J. and Offit, K. and Purdue, M.P. and Rais, M. and Riby, J. and Roman, E. and Rothman, N. and Salles, G. and Severi, G. and Severson, R.K. and Skibola, C.F. and Slager, S.L. and Smith, A. and Smith, M.T. and Southey, M.C. and Staines, A. and Teras, L.R. and Thompson, C.A. and Tilly, H. and Tinker, L.F. and Tjonneland, A. and Turner, J. and Vajdic, C.M. and Vermeulen, R.C.H. and Vijai, J. and Vineis, P. and Virtamo, J. and Wang, Z. and Weinstein, S. and Witzig, T.E. and Zelenetz, A. and Zeleniuch-Jacquotte, A. and Zhang, Y. and Zheng, T. and Zucca, M. and Clarke, A.E., McGill University Health Center [Montreal] (MUHC), Oklahoma Medical Research Foundation (OMRF), Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), LS IRAS EEPI GRA (Gezh.risico-analyse), dIRAS RA-2, and dIRAS RA-I&I RA

Subjects
Oncology, medicine.medical_specialty, Immunology, Single-nucleotide polymorphism, Genome-wide association study, [SDV.CAN]Life Sciences [q-bio]/Cancer, lymphoma, Human leukocyte antigen, Bioinformatics, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 03 medical and health sciences, 0302 clinical medicine, immune system diseases, Internal medicine, medicine, SNP, 030203 arthritis & rheumatology, Systemic lupus erythematosus, business.industry, General Medicine, medicine.disease, Systemic lupus, Lupus Nephritis, Risk of diffuse large B-cell lymphoma, 3. Good health, Lymphoma, 030220 oncology & carcinogenesis, business, Diffuse large B-cell lymphoma, IRF5, malignancy
Abstract

Objective: Determinants of the increased risk of diffuse large B-cell lymphoma (DLBCL) in SLE are unclear. Using data from a recent lymphoma genomewide association study (GWAS), we assessed whether certain lupus-related single nucleotide polymorphisms (SNPs) were also associated with DLBCL. Methods: GWAS data on European Caucasians from the International Lymphoma Epidemiology Consortium (InterLymph) provided a total of 3857 DLBCL cases and 7666 general-population controls. Data were pooled in a random-effects meta-analysis. Results: Among the 28 SLE-related SNPs investigated, the two most convincingly associated with risk of DLBCL included the CD40 SLE risk allele rs4810485 on chromosome 20q13 (OR per risk allele=1.09, 95% CI 1.02 to 1.16, p=0.0134), and the HLA SLE risk allele rs1270942 on chromosome 6p21.33 (OR per risk allele=1.17, 95% CI 1.01 to 1.36, p=0.0362). Of additional possible interest were rs2205960 and rs12537284. The rs2205960 SNP, related to a cytokine of the tumour necrosis factor superfamily TNFSF4, was associated with an OR per risk allele of 1.07, 95% CI 1.00 to 1.16, p=0.0549. The OR for the rs12537284 (chromosome 7q32, IRF5 gene) risk allele was 1.08, 95% CI 0.99 to 1.18, p=0.0765. Conclusions: These data suggest several plausible genetic links between DLBCL and SLE. © 2017 BMJ Publishing Group. All rights reserved.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results